Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04904120 · ClinicalTrials.gov registry record · Phase 1

Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy

A Phase 1 study, sponsored by Perspective Therapeutics.

Completed
Registry status
Phase 1
Development phase
7
Enrollment target

NCT04904120: Completed Phase 1 study, sponsored by Perspective Therapeutics.

NCT04904120 is a Phase 1 study that has completed, run by Perspective Therapeutics. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04904120, a Phase 1 study, has completed, sponsored by Perspective Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
7 participants
Enrollment target

Study Summary

The study hypothesis is that new imaging agents \[203Pb\]VMT01 and \[68Ga\]VMT02 can be safely used in humans without independent biological effect and can be used to image melanoma tumors expressing the melanocortin sub-type 1 receptor (MC1R) by SPECT/CT and PET/CT imaging modalities respectively.

Primary Outcome

Adverse Events (AEs) will be assessed for severity according to CTCAE v5.0 and for relatedness to each of the investigative imaging agents (\[203Pb\]VMT01 and \[68Ga\]VMT02). Assessments attributed as possibly, probably, or definitely related to the imaging agent will be considered related.

Interventions

  • DRUG [203Pb]VMT01
  • DRUG [68Ga]VMT02

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2021-03-05
Est. Completion 2022-09-20
Phase Phase 1
Perspective Therapeutics

4 total trials

What the finished NCT04904120 record still lists

NCT04904120 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).

The record links to 0 conditions, and to 2 interventions - of which [203Pb]VMT01 is the first listed.

NCT04904120 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04904120 about?

NCT04904120 is a clinical study titled "Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy". The study hypothesis is that new imaging agents \[203Pb\]VMT01 and \[68Ga\]VMT02 can be safely used in humans without independent biological effect and can be used to image melanoma tumors expressing the melanocortin sub-type 1 receptor (MC1R) by SPECT/CT and PET/CT imaging modalities respectively.

What is the current status of trial NCT04904120?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2021-03-05. Estimated completion is 2022-09-20.

What interventions are being tested in trial NCT04904120?

The interventions under investigation include: [203Pb]VMT01 (DRUG), [68Ga]VMT02 (DRUG).

Who is sponsoring clinical trial NCT04904120?

This trial is sponsored by Perspective Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04904120's enrollment target sits among peer trials

7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04904120, the US trial registry maintained by the National Library of Medicine. NCT04904120 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.